Contemporary treatment of mitral valve disease with transcatheter mitral valve implantation
© 2022. The Author(s)..
BACKGROUND: Transcatheter mitral valve implantation (TMVI) with self-expanding (SAV) or balloon-expandable (BAV) valves are rising as promising treatment options for high-risk patients with symptomatic mitral valve (MVD) disease unsuitable for alternative treatment options.
AIMS: The aim of this study was to examine the clinical, procedural and outcome parameters of patients undergoing SAV or BAV for MVD.
METHODS: In this observational and single-center case series, fifteen consecutive patients treated with the Tendyne Mitral Valve System (SAV) and thirty-one patients treated with SAPIEN prosthesis (BAV) were included.
RESULTS: The patients (aged 78 years [interquartile range (IQR): 65.5 to 83.1 years], 41% women, EuroSCORE II 10.3% [IQR: 5.5 to 17.0%] were similar regarding baseline characteristics, despite a higher rate of prior heart valve surgery and prevalence of MV stenosis in the SAV-group. At discharge, the SAV-group had a mean transvalvular gradient of 4.2 mmHg, whereas the BAV-group had a mean transvalvular gradient of 6.2 mmHg. None or trace paravalvular leakage (PVL) was assessed in 85% in SAV-group and 80% in the BAV-group. 320 day all-cause and cardiac mortality rates were comparable in both groups (SAV: 26.7% vs BAV: 20%, p = 0.60). Four deaths occurred early in the SAV-group until 32 days of follow-up.
CONCLUSIONS: In high-risk patients with MVD, TMVI presents a promising treatment option with encouraging mid-term outcomes and good valve durability. TMVI either with BAV or SAV may be developed to an established treatment option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Clinical research in cardiology : official journal of the German Cardiac Society - 112(2023), 5 vom: 01. Mai, Seite 571-584 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wienemann, Hendrik [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Heart valve prosthesis |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00392-022-02095-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346240131 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346240131 | ||
| 003 | DE-627 | ||
| 005 | 20231226030939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00392-022-02095-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346240131 | ||
| 035 | |a (NLM)36107228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wienemann, Hendrik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contemporary treatment of mitral valve disease with transcatheter mitral valve implantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Transcatheter mitral valve implantation (TMVI) with self-expanding (SAV) or balloon-expandable (BAV) valves are rising as promising treatment options for high-risk patients with symptomatic mitral valve (MVD) disease unsuitable for alternative treatment options | ||
| 520 | |a AIMS: The aim of this study was to examine the clinical, procedural and outcome parameters of patients undergoing SAV or BAV for MVD | ||
| 520 | |a METHODS: In this observational and single-center case series, fifteen consecutive patients treated with the Tendyne Mitral Valve System (SAV) and thirty-one patients treated with SAPIEN prosthesis (BAV) were included | ||
| 520 | |a RESULTS: The patients (aged 78 years [interquartile range (IQR): 65.5 to 83.1 years], 41% women, EuroSCORE II 10.3% [IQR: 5.5 to 17.0%] were similar regarding baseline characteristics, despite a higher rate of prior heart valve surgery and prevalence of MV stenosis in the SAV-group. At discharge, the SAV-group had a mean transvalvular gradient of 4.2 mmHg, whereas the BAV-group had a mean transvalvular gradient of 6.2 mmHg. None or trace paravalvular leakage (PVL) was assessed in 85% in SAV-group and 80% in the BAV-group. 320 day all-cause and cardiac mortality rates were comparable in both groups (SAV: 26.7% vs BAV: 20%, p = 0.60). Four deaths occurred early in the SAV-group until 32 days of follow-up | ||
| 520 | |a CONCLUSIONS: In high-risk patients with MVD, TMVI presents a promising treatment option with encouraging mid-term outcomes and good valve durability. TMVI either with BAV or SAV may be developed to an established treatment option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heart valve prosthesis | |
| 650 | 4 | |a Mitral valve disease | |
| 650 | 4 | |a Tendyne | |
| 650 | 4 | |a Transcatheter mitral valve implantation | |
| 650 | 4 | |a Valve-in-valve | |
| 700 | 1 | |a Mauri, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Ochs, Laurin |e verfasserin |4 aut | |
| 700 | 1 | |a Körber, Maria Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Eghbalzadeh, Kaveh |e verfasserin |4 aut | |
| 700 | 1 | |a Iliadis, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Halbach, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Wahlers, Thorsten |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Adam, Matti |e verfasserin |4 aut | |
| 700 | 1 | |a Kuhn, Elmar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical research in cardiology : official journal of the German Cardiac Society |d 2006 |g 112(2023), 5 vom: 01. Mai, Seite 571-584 |w (DE-627)NLM161855350 |x 1861-0692 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:571-584 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00392-022-02095-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2023 |e 5 |b 01 |c 05 |h 571-584 | ||